You just read:

Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer

News provided by

Soligenix, Inc.

Apr 18, 2019, 07:00 ET